Effects of different statins application methods on plaques in patients with coronary atherosclerosis

Table 3 Medication application

Item	Group I (n = 32)	Group II (n = 39)	Group III (n = 29)	P value
Baseline
Aspirin	34.3 (11)	23.1 (9)	34.5 (10)	0.48
β-receptor blocker	15.6 (5)	7.7 (3)	20.7 (6)	0.30
ACEI/ARB	15.6 (5)	10.3 (4)	10.3 (3)	0.75
CCB	12.5 (4)	17.9 (7)	24.1 (7)	0.50
Statins	9.4 (3)	7.7 (3)	13.8 (4)	0.70
Glucose-lowering treatment	18.8 (6)	7.7 (3)	17.2 (5)	0.32
Follow-up
Aspirin	28.1 (9)	20.5 (8)	34.5 (10)	0.43
β-receptor blocker	12.5 (4)	7.7 (3)	20.7 (6)	0.30
ACEI/ARB	18.8 (6)	12.8 (5)	13.8 (4)	0.77
CCB	12.5 (4)	12.8 (5)	17.2 (5)	0.84
Glucose-lowering treatment	18.8 (6)	10.3 (4)	17.2 (5)	0.55
Types of statins during follow-up				0.27
Atorvastatin	46.9 (15)	51.3 (20)	58.6 (17)
Simvastatin	31.3 (10)	33.3 (13)	27.6 (8)
Pravastatin	3.1 (1)	0 (0)	3.4 (1)
Rosuvastatin	15.6 (5)	12.8 (5)	10.3 (3)
Fluvastatin	3.1 (1)	2.6 (1)	0 (0)

Values are expressed as % (n). ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; CCB: Calcium channel blocker.